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Mutator phenotypes of common polymorphisms and missense
mutations in MSH2
Karin Drotschmann, Alan B. Clark and Thomas A. Kunkel
Hereditary non-polyposis colorectal cancer (HNPCC) is
associated with germline mutations in the DNA
mismatch repair gene hMSH2 [1], the human
homologue of the Escherichia coli MutS gene. These
are mostly nonsense, frameshift or deletion mutations
that result in loss of intact protein and complete
inactivation of DNA mismatch repair. However, cancer is
also associated with hMSH2 missense mutations that
are merely inferred to be deleterious because they
result in non-conservative substitutions of amino acids
that are highly conserved among MutS family proteins.
Moreover, sequence polymorphisms exist in hMSH2
that also change conserved amino acids but whose
functional consequences and relationship to cancer are
uncertain. Here, we show that yeast strains harboring
putative equivalents of three hMSH2 polymorphisms
have elevated mutation rates. Mutator effects were also
observed for yeast equivalents of hMSH2 missense
mutations found in HNPCC families and in an early
onset colon tumor. Several distinct phenotypes were
observed, indicating that these missense mutations
have differential effects on MSH2 function(s). The
results suggest that cancer may be associated with
even partial loss of hMSH2 function and they are
consistent with the hypothesis that polymorphisms in
hMSH2 might predispose humans to disease. 
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Results and discussion
Table 1 lists seven hMSH2 missense mutations that
change conserved amino acids in hMSH2, the last six of
which have unknown functional consequences. We exam-
ined their effects on mutation rates in two yeast model
systems. One system [2] examines the ability of yeast
MSH2 (yMSH2) mutant alleles homologous to the human
mutations (Figure 1) to reduce the high mutation rate of a
msh2– yeast strain or to elevate the low mutation rate of a
wild-type strain. The other system [3] examines the domi-
nant mutator effect produced by coexpression of wild-type
hMSH2 and hMSH6 in wild-type yeast, thought to result
from formation of a human MutSα complex that binds to
and prevents correction of replication errors.
We first examined missense mutations anticipated to inac-
tivate mismatch repair because of their known association
with HNPCC [1]. For example, an R524P mutation (using
single-letter amino acid code) in hMSH2 has been found
in an ovarian tumor of an HNPCC patient [4]. A cell line
derived from this tumor exhibits microsatellite instability
[4,5] and is defective in mismatch-repair activity [6].
When the homologous R542P mutation in yMSH2 was
expressed from the GAL10 promoter in a 2µ plasmid in a
msh2 strain (all MSH2p mutants were expressed as con-
firmed by immunoblot analysis), it did not reduce the high
rate of single-base deletions at an (A)14 run in the LYS2
gene or the rate of forward mutations at the canavanine
(CAN) locus (Table 2). In contrast, expression of the wild-
type yMSH2 gene from the GAL10 promoter or from the
MSH2 promoter in an ARS-CEN plasmid reduced the
mutation rate at both loci [2] (Table 2). For hMSH2, coex-
pression of wild-type hMSH2p (from a GAL10 promoter)
with hMSH6p (from a GAL1 promoter) in wild-type yeast
elevated the mutation rate by 3,900-fold (Table 3). In con-
trast, coexpression of hMSH2p(R524P) with hMSH6p had
no effect on the mutation rate [3] (Table 3). Consistent
with loss of the dominant mutator effect, extracts of cells
coexpressing hMSH2p(R524P) with hMSH6p do not yield
a band shift with a mismatched oligonucleotide [3]; a
similar loss of band shift capacity was observed with the
homologous yeast proteins (data not shown). The data
from the two assays are consistent with results with the
human tumor cell line [4–6] and suggest that the arginine
to proline mutation in both yeast and human MSH2
strongly inactivates mismatch repair.
Yeast carrying the msh2 missense mutations P640L [7] and
C716F [8] (Table 1, Figure 1), which are homologous to
the HNPCC msh2 mutations P622L and C697F, respec-
tively, also failed to fully complement a msh2 strain
(Table 2), suggesting inactivation of mismatch repair. As
for R524P, the human P622L mutant abolished the domi-
nant mutator effect (Table 3) and ability to cause a band
shift (data not shown, but for example, see Figure 3 in
[3]). Thus, these mutants might confer a defect in MutSα
heterodimer formation and/or nucleic-acid binding,
perhaps resulting from a change in protein conformation
due to non-conservative substitutions involving proline.
The mutation rates seen when the yeast homologues of
the three HNPCC mutants were expressed from the
GAL10 promoter were lower than when expressed from
the MSH2 promoter (Table 2), suggesting that repair was
not completely abolished. These expression-related dif-
ferences in rates were not the same for the three mutants,
which also differed in ability to confer a dominant mutator
effect at the LYS2 locus when expressed in wild-type
yeast (Table 2). Thus, although these missense mutations
clearly affected mismatch repair function, their pheno-
types were distinct.
We next examined an MSH2 missense mutation (D506Y)
found in the germ line of a Korean patient with early
onset colon cancer [9]. The homologous D524Y mutant in
yMSH2 was partially defective in complementing the
mutator phenotype of a msh2 strain (Table 2; for example,
a 72-fold effect at the (A)14 run). However, as shown in
Table 2, it retained some mismatch repair function as evi-
denced by its ability to reduce the mutator phenotype of
the msh2 strain when overexpressed (310-fold at the LYS2
locus; compare 620 × 10–6 with 2 × 10–6; and 24-fold at the
CAN locus). Moreover, coexpression of hMSH2p(D506Y)
with hMSH6p yielded a 4,600-fold dominant mutator
phenotype in a wild-type yeast strain (Table 3) and a cell
extract that retained the ability to cause a band shift (data
not shown), suggesting that the D506Y mutant interacts
with hMSH6p and that the mutant MutSα complex binds
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Table 1
MSH2 missense mutations examined in this study.
Mutation in Homologous mutation Allele frequency Role in Role in sporadic or early
hMSH2 in yMSH2 HNPCC* onset colon cancer*
R524P R542P ND +† –
P622L P640L ND + [7] –
C697F C716F ND + [8] –
D506Y D524Y ND – + [9]
G322D G317D 1–6% [8,10–14] + [17] + [15,16]
Q419K Q430K 1% [18] – –
L390F L402F 2% [18] + [19] –
The mutations are indicated in the single-letter amino-acid code.
*These columns indicate whether a particular polymorphism has (+) or
has not (–) been implicated in the development of HNPCC, or of
sporadic or early onset colon cancer. †Although described as HNPCC
[4], this patient did not fulfill the Amsterdam criteria and had ovarian
cancer. ND, not determined. 
Figure 1
Representations of MSH2. (a) Putative
functional regions of hMSH2. An amino-terminal
DNA-binding region, a region that interacts with
the mismatch-repair protein MutL (blue), and a
carboxy-terminal MutS dimerization region are
suggested by studies of deletion mutants of
E. coli MutS [20]. Amino acids 827–846
comprise a helix-turn-helix motif suggested to
interact with yMSH6 [21]. Studies of hMSH2
have implicated two regions in
heterodimerization of hMSH2 with MSH3 and
MSH6 (grey) [22]. Also indicated are the
Walker A and B motifs required for ATP binding
and hydrolysis [23]. The numbers above the
boxes indicate amino acids delineating the
functional regions; those below correspond to
the missense mutations. (b) Alignment of
human, mouse, rat and yeast MSH2. The
numbers above the alignment correspond to
hMSH2 amino-acid positions; those below
correspond to yMSH2 residues. The missense
mutations are indicated below the alignment.
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to mismatches. The data suggest that even partial inacti-
vation of mismatch repair might be associated with early
onset colorectal cancer.
This suggestion prompted an analysis of missense muta-
tions that replace conserved amino acids in hMSH2 and
that are common variant alleles in humans. An example is
the non-conservative substitution of aspartic acid for
Gly322, resulting from a glycine→alanine nucleotide tran-
sition. This allele has been detected at a 1–6% frequency
in studies of patients with sporadic colorectal cancer and
unaffected controls [8,10–16], and has also been found in a
family which fulfilled the Amsterdam criteria for HNPCC
[17]. Thus, the G322D allele is common and has been
considered a sequence variant unrelated to cancer, a possi-
ble low-penetrance allele, or a mutation predisposing to
HNPCC. Yeast carrying the putative equivalent mutation
G317D (Figure 1) partially complemented the mutator
defect at the LYS2 or CAN locus in a msh2 strain when
expressed from the GAL10 promoter (Table 2). Comple-
mentation was ineffective, however, when expressed from
the yMSH2 promoter, suggesting that the G317D msh2
mutation partially inactivates mismatch repair. When the
human G322D msh2 mutant was expressed with hMSH6p
in yeast, it produced a dominant mutator effect (Table 3)
and a band shift similar to that observed with the wild-
type MSH2p (data not shown). These results suggest that
hmsh2p (G322D) interacts with hMSH6p and that the
complex binds to mismatches. Thus, a defect in mismatch
repair suggested by results with the putative homologous
yeast mutant could reflect events in the repair pathway
that are downstream of these interactions (for example, a
defect in other protein–protein or substrate interactions)
or required for a protein conformational change. An impor-
tant caveat is that the alignments in Figure 1 are insuffi-
cient to establish unequivocally that Gly317 in yMSH2 is
functionally equivalent to Gly322 in hMSH2.
Two other missense alleles whose functional conse-
quences have not been reported are Q419K and L390F
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Table 2
Effect of expression of MSH2 mutants on mutation rates of msh2 and MSH2 yeast strains.
msh2 strain MSH2 strain
(A)14 Canavanine resistance (A)14
ARS-CEN GAL10 2µ ARS-CEN GAL10 2µ ARS-CEN GAL10 2µ
None ND‡ 620 (8,900) ND 4.7 (47) ND 0.14 (0.9)
MSH2 0.64 (1) 0.07 (1) 0.5 (1) 0.10 (1) 0.15 (1) 0.16 (1)
His–MSH2 ND 0.55 (1) ND 0.20 (1) ND 0.90 (1)
R542P 590* (920) 210*† (380) 7.3* (15) 6.9*† (35) 0.30 (2) 620*† (690)
P640L 520* (810) 52*† (95) 3.2* (6) 1.3*† (7) 0.20 (1.3) 0.60† (0.7)
C716F 220* (340) 120*† (220) 3.3* (7) 2.7*† (14) 0.70* (4.7) 4.3† (4.8)
D524Y 46* (72) 2.0*† (4) 0.6 (1.2) 0.20† (1) 0.20 (1.3) 0.90† (1)
G317D 350* (550) 28* (400) 8.7* (17) 0.40 (4) 0.52* (3.5) 1.1 (7)
Q430K 37* (58) 230* (3,300) 0.3 (0.6) 2.5* (25) 0.25 (1.7) 0.20 (1.3)
L402F 37* (58) 290* (4,100) 0.4 (1) 2.1* (20) 0.25 (1.7) 0.20 (1.3)
All mutation rates are × 106 and should be compared with the rates
shown for the equivalent wild-type MSH2 (see third row). Rates and
95% confidence limits (data not shown) were calculated, as described
in [3], from multiple (typically 12) independent determinations. Fold-
increase over the wild-type rate is indicated within the brackets. ND,
not determined. *These rates are higher than in the wild-type
(non-overlapping confidence intervals). †These mutants carry a
sequence encoding the His6 epitope tag at the 5′ end of the gene.
‡Although this value was not determined, it can be assumed that both
vector constructs without the MSH2 gene result in the same mutation
rate, as all cultures were grown in the same media. 
Table 3
Effects of human MutSα complexes on Lys+ reversion rate in a
yeast MSH2, lys::InsE-A14 strain.
Plasmid Mutation rate Fold-increase
(× 106) over MSH2
Vectors 0.13 1
hmsh2 + hMSH6 510 3,900
hmsh2(R524P) + hMSH6 0.20 1
hmsh2(P622L) + hMSH6 0.14 1
hmsh2(D506Y) + hMSH6 610 4,600
hmsh2(G322D) + hMSH6 440 3,400
hmsh2(Q419K) + hMSH6 500 3,800
hmsh2(L390F) + hMSH6 420 3,200
(Table 1). The Q419K mutation was identified in a colon
cancer patient, but it was not implicated in the cancer and
was described as a polymorphism [18]. The L390F muta-
tion has also been found in colon cancer patients and is
viewed as a possible HNPCC mutation [19] or as a poly-
morphism [18,19]. Yeast carrying the putative equivalent
mutations, Q430K and L402F, yield significant mutator
effects (Table 2), indicating a functional defect. Some
function is retained though, because when expressed
from the yMSH2 promoter, the Q430K and L402F
mutants reduced the mutator defect at the LYS2 or CAN
locus in a msh2 strain by more than 10-fold (Table 2).
Unexpectedly, when expressed from the GAL10 pro-
moter, the Q430K and L402F mutants were actually less
efficient in complementing the mutator phenotype, a
result opposite to that seen with the other missense
mutants. Expression of the Q430K and L402F mutants
from either plasmid did not confer a dominant mutator
effect to a wild-type yeast strain (Table 2). When the
human L390F and Q419K msh2 mutants were expressed
with hMSH6p, they produced dominant mutator effects
(Table 3) and band shifts like those observed with wild-
type MSH2p (data not shown).
These data suggest that mismatch repair defects are con-
ferred by seven different msh2 missense mutations, several
of which are homologous to mutations in hMSH2 that have
been implicated in cancer and three of which might be
common in the normal human population. The phenotypes
of the msh2 mutations were complex, suggesting that the
mutations alter MSH2p function in different ways. Because
the alignments in Figure 1 do not by themselves establish
functional equivalence, and as there are obvious differences
between yeast and human cells, additional functional and
population-based studies in humans will be required to
determine whether these hMSH2 polymorphisms are clini-
cally relevant. Nonetheless, the defects reported here with
the yeast G317D, L402F and Q430K mutants are consis-
tent with the hypothesis that common polymorphisms in
hMSH2 may predispose humans to disease.
Materials and methods
Strains, plasmids, genetic and biochemical methods
All strains, plasmids and methods used in this work have been described
previously [2,3].
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